Can Industry Learn to Share? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Can Industry Learn to Share?
The regulators are doing it. But industry's fear of sharing information may leave them behind.


Pharmaceutical Technology
Volume 33, Issue 7, pp. 14


Angie Drakulich
The US Food and Drug Administration has been sharing inspection information with its regulatory counterparts in the European Union and Australia since last July as part of a pilot program under the federal Interagency Working Group on Import Safety. Now, industry is forming an international pharmaceutical supply chain consortium known as Rx–360 to, among other objectives, create a shared program for auditing suppliers.

The growing consortium is very similar to a model for third-party shared audits of active pharmaceutical ingredient suppliers run by the European Chemical Industry Council's Active Pharmaceutical Ingredients Committee.

But is industry really willing to join in the sharing game? We're all taught to share from an early age, but somewhere along the line, we get caught up in competition and slowly decrease our eagerness to confide in peers. Competition is important—it is the foundation of our economy—and in the field of science, intellectual property rights and company proprietary information require individuals to remain private about the details of their work. But perhaps this hiding of information has gone too far. There must be a way industry can learn to share without giving up all its trade secrets.

Consider this: To meet all the new requirements for securing the supply chain, industry would have to conduct 800,000 audits per year, said Rx-360's Martin Van Trieste at the June consortium launch meeting. Unless pharma firms are planning to go on a massive hiring spree—perhaps alleviating the US unemployment rate along the way—to conduct these audits, it may be time for industry to start sharing.

Angie Drakulich is the managing editor of Pharmaceutical Technology.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here